Compare Huntington Ingalls Industries Inc (HII) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Huntington Ingalls Industries Inc trades at $264.2 (market cap $10.16B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Huntington Ingalls Industries Inc is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays a 2.14% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 30 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HII | SYRE | |
|---|---|---|
Market Cap | $10.16B | $7.52B |
Volume | 503,029 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $453.73 | $108.92 |
52-Week Low | $257.05 | $22.18 |
Typical Hold Time | 30 Days | 0 Days |
Enterprise Value | $13.08B | $6.52B |
Dividend Yield | 2.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $257.84, down 2.34% today, amid a bearish technical signal but strong fundamentals. The company demonstrates consistent earnings beats, with Q2 2026 EPS of $5.27 exceeding expectations by 39%. Recent contract wins, including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders, bolster its $57.3 billion backlog. Valuation metrics appear attractive with a P/E of 15.36 and P/S of 0.77.
The investment case balances strong defense sector positioning against near-term technical weakness. Analyst consensus targets $357.00, implying 38% upside, with 41% buy ratings. Key risks include execution on large contracts and defense budget fluctuations. The current price near support at $258 presents a potential entry point for long-term investors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
